As discussed in later sections of this review, SDD formulations have recently demonstrated evidence of safety and efficacy in humans with a variety of other diseases and conditions as well, including pemphigoid, rheumatoid arthritis (RA), post-menopausal (PM) osteopenia, type II diabetes, cardiovascular diseases and a rare and fatal lung disease, lymphangioleiomyomatosis (see below).